5 Questions on Advanced Breast Cancer

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Roman Fabbricatore

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Jorge Nieva, MD

July 14th 2025

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Tim Cortese

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Russ Conroy

Applying Clinical Trials to Patient Cases: The Melanoma Landscape

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Related Content

ONCOLOGY Staff

July 26th 2025

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Roman Fabbricatore

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Jorge Nieva, MD

July 14th 2025

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Tim Cortese

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Russ Conroy